Summary
CLAEYSPHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.8m and a net result of €142,030. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 69% of 6,658 sector peers (NACE 64, financial year 2025). The company has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- CLAEYSPHARMA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest, 9920 Lievegem (Lovendegem), Bredestraat Kouter 69” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Daily managementWho may handle the everyday running of the business without the full board.
- The board decides whether the delegates act alone or jointly
- Board ruleHow the board is made up, meets and takes decisions.
- “Met of zonder beperking van duur, 1” (deed in Dutch)“Bijzondere volmacht aan derde aangestelde, gezamenlijk indien meerdere bestuurders, college met voorzitter, handelt als raadsvergadering” (deed in Dutch)
Capital, shares and profit
- Profit allocationHow profit is distributed; a BV may only pay out after a balance-sheet and liquidity test.
- “Algemene vergadering, bestuursorgaan” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Saturday of June at 20:00
Oversight and winding up
- Auditor ruleHow a statutory auditor is appointed and what they check, if the company has one.
- One provision in the deed